Skip to content
PatentBrief
Get alertsTop ↑

Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10

This patent describes specific engineered cells that contain parts of the AAVrh.10 virus and an additional non-viral genetic sequence, designed to produce gene therapy vectors.

Granted 2022ActiveExpires 2041Owned by University of PennsylvaniaInvented by James M. Wilson, Mauricio R. Alvira, Guangping Gao

Original patent title: “Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby”

Plain-English explanation by SahiLast reviewed · October 31, 2026

This patent describes specific engineered cells that contain parts of the AAVrh.10 virus and an additional non-viral genetic sequence, designed to produce gene therapy vectors. Granted to University of Pennsylvania in 2022 with 20 claims, and it is expected to expire in 2041.

Coverage

What does this patent actually cover?

The patent claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → a "cultured host cell" that has been genetically modified. This cell contains a "recombinant nucleic acid molecule" (an engineered piece of DNA) that carries instructions for two main things: first, making specific parts of the AAVrh.10 virus, such as its "vp1 capsid protein" (amino acids 1 to 738 of SEQ ID NO: 81), or vp2, or vp3, or specific nucleotide sequences (like 845 to 3058 of SEQ ID NO: 59); and second, a "heterologous non-AAV sequence." This "heterologous" part is the therapeutic genetic material that a gene therapy aims to deliver. For example, a cell could be engineered to produce the outer shell of the AAVrh.10 virus, while also carrying the gene for a missing protein in a patient. Some claims also specify the presence of a "functional rep gene" (which helps the virus replicate) and that the recombinant molecule can be a "plasmid" (a common way to introduce DNA into cells).

The gap

What does this patent NOT cover?

  • Does not cover AAVrh.10 sequences or proteins existing outside of a cultured host cell.
  • Does not cover host cells containing AAVrh.10 components without an additional "heterologous non-AAV sequence."
  • Does not cover other types of adeno-associated viruses (AAVs) beyond the specific AAVrh.10 variant described.
  • Does not cover gene therapy vectors that use entirely different viral or non-viral delivery systems.
  • Does not cover cells containing only the AAV 'rep gene' without the specified capsid protein or nucleotide sequences.

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 11499167
StatusActive
FieldBiotech & Medicine
AssigneeUniversity of Pennsylvania
InventorsJames M. Wilson, Mauricio R. Alvira, Guangping Gao
Filed2021
Granted2022
Expires2041
Claims20
Times cited0
LitigationNone on record
Value · $88K–$281KModest

What made this novel

The noveltynoveltyThe requirement that an invention be different from anything publicly known before its priority date.Read more → lies in precisely defining and claiming the use of specific AAVrh.10 capsid protein sequences (like VP1, VP2, VP3 from SEQ ID NO: 81) or specific nucleic acid sequences (from SEQ ID NO: 59) within a cultured host cell, specifically combined with a "heterologous non-AAV sequence" for gene delivery applications. This focuses on a particular, potentially advantageous, AAV serotype for vector production.

The Patent Drawing

Representative patent drawing for Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby (US 11499167)
Representative figure · US 11499167All figures on Google Patents →
Method of detecting and/or ide…(Primary claim)biotechpharmaceuticalgene editing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

Manufacturing of gene therapy vectors in bioreactors

02

Research into new gene therapies for genetic disorders

03

Production of AAV-based vaccines in laboratory settings

Why it matters

The bigger picture

Adeno-associated viruses (AAVs) are widely used in gene therapy because they can deliver genetic material into cells safely and efficiently. The University of Pennsylvania, particularly through Dr. James Wilson's lab, has been a pioneer in identifying and developing different AAV serotypes, like AAVrh.10, which can have unique properties for targeting specific tissues or evading immune responses. This patent protects the specific engineering of cells to produce gene therapy vectors using this particular AAVrh.10 variant, which is crucial for developing new treatments for genetic diseases.

Filed

October 12, 2021

Granted

November 15, 2022

Market context

Who's building on this

Companies in this space

The University of Pennsylvania, through its gene therapy program, continues to be a leader in AAV research and development. Companies like Sarepta Therapeutics, Novartis, and Pfizer are actively developing AAV-based gene therapies, often licensing or building upon foundational AAV technologies developed by academic institutions. Many biotechnology startups also focus on optimizing AAV vectors for various therapeutic applications.

Market impact

The development and patenting of specific AAV serotypes, like AAVrh.10, have significantly expanded the toolkit available for gene therapy. This has enabled the creation of new gene therapy candidates with potentially improved tissue targeting, reduced immunogenicity, or better manufacturing properties. Such patents contribute to the intellectual property landscape that underpins the multi-billion dollar gene therapy market, influencing licensing agreements and competitive strategies among pharmaceutical and biotech companies.

Claim 1 — Plain English

What this patent covers

The patent claims a "cultured host cell" that has been genetically modified. This cell contains a "recombinant nucleic acid molecule" (an engineered piece of DNA) that carries instructions for two main things: first, making specific parts of the AAVrh.10 virus, such as its "vp1 capsid protein" (amino acids 1 to 738 of SEQ ID NO: 81), or vp2, or vp3, or specific nucleotide sequences (like 845 to 3058 of SEQ ID NO: 59); and second, a "heterologous non-AAV sequence." This "heterologous" part is the therapeutic genetic material that a gene therapy aims to deliver. For example, a cell could be engineered to produce the outer shell of the AAVrh.10 virus, while also carrying the gene for a missing protein in a patient. Some claims also specify the presence of a "functional rep gene" (which helps the virus replicate) and that the recombinant molecule can be a "plasmid" (a common way to introduce DNA into cells).

The clever bit

The novelty lies in precisely defining and claiming the use of specific AAVrh.10 capsid protein sequences (like VP1, VP2, VP3 from SEQ ID NO: 81) or specific nucleic acid sequences (from SEQ ID NO: 59) within a cultured host cell, specifically combined with a "heterologous non-AAV sequence" for gene delivery applications. This focuses on a particular, potentially advantageous, AAV serotype for vector production.

What it does not cover

  • Does not cover AAVrh.10 sequences or proteins existing outside of a cultured host cell.
  • Does not cover host cells containing AAVrh.10 components without an additional "heterologous non-AAV sequence."
  • Does not cover other types of adeno-associated viruses (AAVs) beyond the specific AAVrh.10 variant described.
  • Does not cover gene therapy vectors that use entirely different viral or non-viral delivery systems.
  • Does not cover cells containing only the AAV 'rep gene' without the specified capsid protein or nucleotide sequences.

Patent timeline

Filing

Application submitted to the patent office

Publication

Application published, typically 18 months after filing

Grant

Patent officially issued

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Moderate

Citation count

0/40

No citations yet

Claim breadth

13/20

Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →

Recency

20/20

Granted within 5 years

Assignee scale

20/20

Major company or institution

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Modest

$88K – $281K

Midpoint $176K · 14.9 yr remaining · industry ×3.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

20 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Citations

Patent lineage

Cites earlier patents

86

earlier patents this invention cites as foundations

View prior art →

Cite this patent

Wilson, J. M., Alvira, M. R., & Gao, G. (2022). Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10 (U.S. Patent No. 11,499,167). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/11499167/method-of-detecting-andor-identifying-adeno-associated-virus-aav-sequences-and-i

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US11499167"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:biotech patents →pharmaceutical patents →gene editing patents →

Common Questions

Frequently Asked Questions

What does Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10 cover?

This patent describes specific engineered cells that contain parts of the AAVrh.10 virus and an additional non-viral genetic sequence, designed to produce gene therapy vectors.

Who owns patent US 11499167?

University of Pennsylvania owns this patent, granted in 2022.

When does this patent expire?

This patent is expected to expire on October 12, 2041, when the invention enters the public domain.

What problem does this patent solve?

Adeno-associated viruses (AAVs) are widely used in gene therapy because they can deliver genetic material into cells safely and efficiently. The University of Pennsylvania, particularly through Dr. James Wilson's lab, has been a pioneer in identifying and developing different AAV serotypes, like AAVrh.10, which can have unique properties for targeting specific tissues or evading immune responses. This patent protects the specific engineering of cells to produce gene therapy vectors using this particular AAVrh.10 variant, which is crucial for developing new treatments for genetic diseases.

What does this patent NOT cover?

Does not cover AAVrh.10 sequences or proteins existing outside of a cultured host cell.

Same assignee

More from University of Pennsylvania

View all →
US 11357868·2022

New Adeno-Associated Virus Capsids for Gene Therapy

Patent monitoring

Get notified when University of Pennsylvania files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: October 31, 2026 · PatentBrief is not a law firm and this is not legal advice.